Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000932471-25-000196·Monte Rosa Therapeutics, Inc.
Schedule 13G ownership disclosure
Monte Rosa Therapeutics Inc
Common Stock · CUSIP: 61225M102
Event date: 2024-12-31
- Filing-level shares
- 3,156,354
- Percent of class
- 5.13%
- The Vanguard Group
Shares: 3,156,354 · Class: 5.13%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000196
- Form type
- SCHEDULE 13G
- Filer
- Monte Rosa Therapeutics, Inc.
- CIK
- CIK 1826457
- Filed
- Jan 30, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership